AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02085785 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Screened only
Description: Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
Study NCT05547074 — intervention group
Intervention type: PROCEDURE
Intervention: pancreatic cancer surgery
Description: Surgical resection of pancreatic cancer，including radical or palliative surgery
Study NCT03430596 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole
Description: The dose of pramipexole range from 0.375mg/d to 0.75mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
Study NCT03430596 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trihexyphenidyl hydrochloride
Description: he dose of Antan range from 2 mg/d to 4 mg/d , The accurate dose of pramipexole can be adjusted by the patient's condition and tolerance .
Study NCT03454919 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Palbociclib
Description: Drug: palbociclib; ibrance; Pfizer Inc，New York，NY Schedule: Recommended initial dosage 125mg/d，3 weeks on, 1 week off. If grade 3 or 4 adverse events occur during treatment，dosage could be reduced to 100mg/d, even 75mg/d.~Duration: till disease progression or drug intolerance.
Study NCT05780112 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: breathing exercise
Description: * Place one hand on your chest and the other on your stomach.~* Slowly take a deep breath through the nose.~* During inhalation, your hand on your stomach should rise upwards as the air fills the lungs. If it is under your hand on the chest, there should not be much movement.~* Hold your breath and stretch your muscles in a second or two.~* Take air through your nose with your mouth closed and exhale slowly through your mouth by pursing your lips like a whistle.~* Set the time you use when exhaling air to be twice the time you use when exhaling.~* As you exhale, focus on the inward movement of your abdominal hand.
Study NCT01575496 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BrainSTIM Transcranial Stimulator
Description: Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
Study NCT01575496 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BrainSTIM Transcranial Stimulator
Description: Sham tDCS sessions will last 20 minutes.
Study NCT03469830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPMS
Description: Pressure therapy
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch genetic testing online educational video
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Watch genetic testing online educational video
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive post-telephone genetic counseling
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Receive post-telephone genetic counseling
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genetic Counseling
Description: Receive pre-telephone genetic counseling
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Counseling
Description: Receive pre-telephone genetic counseling
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02993068 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02542891 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended CBT
Study NCT02542891 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual (TAU)
Study NCT02372708 — intervention group
Intervention type: DRUG
Intervention: dinitrophenyl(DNP)
Study NCT02372708 — intervention group
Intervention type: RADIATION
Intervention: Radiation
Description: laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
Study NCT02442453 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical application of curenext gel
Description: Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
Study NCT02442453 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
Study NCT00592540 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Unrelated Donor BMT
Description: Unrelated donor bone marrow transplantation has not been performed with these patients in the past
Study NCT00794365 — intervention group
Intervention type: DRUG
Intervention: Varenicline
Description: There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:~Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily~Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water.
Study NCT03403985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (Ca(OH)2)
Description: Ca(OH)2 will be used in this group
Study NCT03403985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate
Description: MTA will be used in this group
Study NCT04412733 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapeutic Pulsed Ultrasound
Description: Patients in pulsed ultrasound group received pulsed ultrasound treatment (frequency: 1000 kHz, intensity: 0.5w/cm2, on-off ratio: 1:2). Pulsed ultrasound treatment were applied with 5-cm2 head Enraf-Nonius Sonopuls 434 ultrasound device.
Study NCT04412733 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Ultrasound
Description: Control group received sham ultrasound treatment
Study NCT02728414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
Study NCT02728414 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: placebo
Description: the patients in this arm will receive placebo intervention
Study NCT01509677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Roflumilast
Description: 500 μg tablet, once daily, oral administration in the morning after breakfast
Study NCT01509677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablet, once daily, oral administration in the morning after breakfast
Study NCT02033590 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biodegradable (purified) surgical silk scaffold
Study NCT00944736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: VSL#3
Description: 1 packet BID
Study NCT00944736 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 inactive packet BID
Study NCT00358332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FMP2.1/AS02A
Description: FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
Study NCT00358332 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rabies vaccine (RabAvert)
Description: RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
Study NCT01965054 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fish Oil Supplement Group
Description: 1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
Study NCT01739660 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegloticase
Description: a single 8 mg iv (in the vein) dose before hemodialysis session
Study NCT02510651 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Melanocyte-keratinocyte suspension
Description: Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
Study NCT02199886 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBH 1
Description: labeled with eight to ten millicurie of 131I
Study NCT02198963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypochlorous acid solution 106 mg/L
Description: test product
Study NCT01757223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdVEGF-All6A+
Description: We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
Study NCT01757223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AdNull
Description: AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
Study NCT04615975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketogenic diet with phytoextracts
Description: Patients were provided with an individualized nutritional ketogenic plan during hospitalization
Study NCT03796754 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: YoBEKA
Description: The teachers and students of the YoBEKA study arm receive a guided YoBEKA practice from an experienced YoBEKA trainer during the regular 4 month intervention period. The YoBEKA program is based on a combination of different, easy to perform exercises appropriate to the school situation, consisting of postures, verses for speech, song and movement, affirmations in movement to promote balance and coordination, and various rest and silence exercises to promote body awareness and relaxation techniques. The teaching is ideologically neutral and without religious background. The participating teachers receive an initial two-hour YoBEKA introductory course. Every 2 weeks there is a one to two-hour training course. The pedagogical specialists are supported once a week by an experienced YoBEKA trainer. The teachers are encouraged to integrate the learned exercises independently and regularly into their everyday school life.
Study NCT04127799 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hospital-Community-Family-Care Management Platform Online
Description: Subjects with Hospital-Community-Family-Care Management Platform online and those with the clinic follow up. In the program, participants were educated on the use of smart health-tracking devices and mobile application (APP) to collect and upload comprehensive data elements related to the risk of AF self-care management. They were also instructed to send text messages, view notifications, and receive individualized guidance on the mobile APP. The general practitioners viewed index of each participant on mobile APP and provided primary care periodically, and cardiologists in regional central hospital offered remote guidance and management if necessary. Outcomes assessed included accomplishments of the program, usability and satisfaction, engagement with the intervention, and changes of AF-related health behaviors.
Study NCT04071730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immulina Dietary Supplementation
Description: Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
Study NCT04071730 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Immulina Dietary Supplementation
Description: Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.
Study NCT02964962 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 29 mm LOTUS Edge™ Valve System
Description: Transcatheter aortic valve replacement
Study NCT02066233 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EG Scan II (transnasal endoscopy)
Study NCT02066233 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endoscopy
Study NCT03963791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Eggshell powder gel
Description: Eggshell powder gel produced from chicken eggs.
Study NCT03963791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Eggshell powder gel
Description: Eggshell powder gel produced from chicken eggs.
Study NCT03963791 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CPP-ACP crème
Description: A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
Study NCT03963791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CPP-ACP crème
Description: A water-based, sugar-free topical cream containing Recaladent (CCP-ACP) which is derived from the milk protein.
Study NCT00628992 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No specific intervention, standard therapy serving as a control group, passive mobilization of the legs
Description: Muscular rehabilitation of the leg
Study NCT00628992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation of the thigh
Description: Muscular rehabilitation of the leg
Study NCT00628992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cycloergometer training
Description: Muscular rehabilitation of the leg
Study NCT00628992 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electrical stimulation of the thigh and cycloergometer training
Description: Muscular rehabilitation of the leg
Study NCT03267186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO
Study NCT03267186 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT00314015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Evaluation of the success rate of implants
Description: Evaluation of the success rate of implants will be followed.
Study NCT00314015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Questionnaires will be used
Study NCT02198963 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% (w/v) Sodium Lauryl Sulfate
Description: positive control
Study NCT02198963 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Physiological Saline, USP
Description: negative control
Study NCT00736437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ME-609
Description: Cream applied topically 6 times daily over the UVR exposed area
Study NCT00736437 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Treatment applied 6 times daily over the UVR exposed area
Study NCT03719352 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: Placebo Gastrocnemius dry needling
Description: Simulate pain with de plastic needle guard in the gastrocnemius muscle
Study NCT00103220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SJG-136
Description: Given IV
Study NCT03886883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise induced hypoalgesia (EIH)
Description: An EIH response was induced by a 3-minute isometric contraction of the hand flexor muscles at 25% of maximal voluntary contraction (MVC).
Study NCT03886883 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Static stretch (SS)
Description: Two bouts of 30 seconds of static stretching (SS) of the knee flexors.
Study NCT03886883 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rest
Description: The participants rested in a seated position for 10 minutes
Study NCT03886883 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conditioned pain modulation (CPM)
Description: A CPM response was induced by way of the cold pressor test.
Study NCT01967914 — intervention group
Intervention type: OTHER
Intervention: PVI
Description: Measurement of PVI (plethysmography variability index)
Study NCT00588588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bronchoscopy
Description: Bronchoscopy procedure
Study NCT00588588 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Clinical pulmonary infection score (CPIS)
Description: Calculate CPIS
Study NCT01883349 — intervention group
Intervention type: PROCEDURE
Intervention: Kidney Transplant
Description: Kidney Transplant Surgery
Study NCT01883349 — intervention group
Intervention type: OTHER
Intervention: No kidney transplant
Description: The control group was made up of subjects without ESRD and were not on the renal transplantation waitlist.
Study NCT03762044 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activity-oriented Proprioceptive Antiedema Therapy (TAPA)
Description: * Health education / patient empowerment.~* Neurodynamic activities oriented to ADL.~* Proprioceptive neuromuscular facilitation exercises oriented to ADL.~* Self-adherent self-adhesive antiedema of low compression.
Study NCT03762044 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Complete Decongestive Therapy (CDT)
Description: * Skin care.~* Kinesitherapy~* Manual lymphatic drainage (MLD)~* Multilayer bandage.~The maintenance phase is based on self-care and the use of compression garments.
Study NCT04614948 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
Study NCT04614948 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ad26.COV2.S
Description: Ad26.COV2.S vaccine will be administered on Day 1 and Day 57 in the double-blind phase. At unblinding visit Ad26.COV2.S vaccine will be administered to participants at Day 57 who have not yet received second vaccination and in newly enrolled participants as either single dose on Day 1 or two doses on Day 1 and Day 57. Single dose of Ad26.COV2.S vaccine will also be administered to participants initially receiving placebo. Single booster dose of Ad26.COV2.S vaccine will be given to participants in the open label phase who have received only a single vaccination with Ad26.COV2.S.
Study NCT04614948 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as IM injection on Day 1 and Day 57.
Study NCT01365312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethanol lock
Description: Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
Study NCT01365312 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Heparinized saline
Description: 0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
Study NCT01192048 — intervention group
Intervention type: OTHER
Intervention: Blood Sample Collection
Description: Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome or genome sequencing.
Study NCT02686736 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-based educational intervention
Description: The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
Study NCT02774642 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBTI-PE
Description: Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence